Copenhagen Pharma Consulting ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 4.4% 6.0% 6.5%  
Credit score (0-100)  0 0 46 38 35  
Credit rating  N/A N/A BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 3,291 1,305 2,931  
EBITDA  0.0 0.0 1,163 -40.3 433  
EBIT  0.0 0.0 1,163 -40.3 433  
Pre-tax profit (PTP)  0.0 0.0 1,159.1 -47.5 432.0  
Net earnings  0.0 0.0 904.0 -37.8 335.7  
Pre-tax profit without non-rec. items  0.0 0.0 1,159 -47.5 432  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 944 906 1,242  
Interest-bearing liabilities  0.0 0.0 1.9 1.9 1.9  
Balance sheet total (assets)  0.0 0.0 1,335 1,246 2,352  

Net Debt  0.0 0.0 -253 -224 -1,350  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 3,291 1,305 2,931  
Gross profit growth  0.0% 0.0% 0.0% -60.4% 124.7%  
Employees  0 0 2 2 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 1,335 1,246 2,352  
Balance sheet change%  0.0% 0.0% 0.0% -6.7% 88.8%  
Added value  0.0 0.0 1,162.6 -40.3 432.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 1.0 -1.0 1.0  

Profitability 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 35.3% -3.1% 14.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 87.8% -2.7% 24.3%  
ROI %  0.0% 0.0% 124.0% -3.7% 40.6%  
ROE %  0.0% 0.0% 95.8% -4.1% 31.3%  

Solidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 70.7% 72.7% 52.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -21.7% 557.6% -311.8%  
Gearing %  0.0% 0.0% 0.2% 0.2% 0.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 1,449.5% 687.8% 273.7%  

Liquidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 3.4 3.7 2.1  
Current Ratio  0.0 0.0 3.4 3.7 2.1  
Cash and cash equivalent  0.0 0.0 254.6 226.3 1,351.7  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 944.0 906.2 1,241.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 581 -20 216  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 581 -20 216  
EBIT / employee  0 0 581 -20 216  
Net earnings / employee  0 0 452 -19 168